A complete response letter (CRL) from the FDA delays a product's entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them. Imagine how much you could save if you could anticipate the FDA's concerns and address them before the agency issues the complete response letter? Now you can.
With a focus on developing lesion-specific solutions for peripheral artery disease, Medtronic announced the U.S. and international launches of the Amphirion Plus Percutaneous Transluminal Angioplasty Catheter for the interventional treatment of atherosclerotically narrowed or occluded leg arteries below the knee. Reuters